辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

交易中 04-16 14:04:52 EDT

25.80

-0.11

-0.43%

最高25.99	最低25.74	成交量1,517万
今开25.81	昨收25.91	日振幅0.95%
总市值1,461亿	流通市值1,459亿	总股本56.63亿
成交额3.92亿	换手率0.27%	流通股本56.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":25.7997,"timestamp":1713290690070,"preClose":25.91,"halted":0,"volume":15168420,"delay":0,"floatShares":5653840796,"shares":5662541291,"eps":0.367372,"marketStatus":"交易中","marketStatusCode":2,"change":-0.1103,"latestTime":"04-16 14:04:52 EDT","open":25.81,"high":25.985,"low":25.74,"amount":392100213.76866,"amplitude":0.009456,"askPrice":25.8,"askSize":1818,"bidPrice":25.79,"bidSize":4330,"shortable":3,"etf":0,"ttmEps":0.367372,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1713297600000},"adr":0,"listingDate":-819144000000,"adjPreClose":25.91,"adrRate":0,"dividendRate":0.063567,"preHourTrading":{"tag":"盘前","latestPrice":25.82,"preClose":25.91,"latestTime":"09:29 EDT","volume":178025,"amount":4609292.6296500005,"timestamp":1713274199087},"postHourTrading":{"tag":"盘后","latestPrice":25.94,"preClose":25.91,"latestTime":"19:59 EDT","volume":2803560,"amount":72638604.423,"timestamp":1713225573197},"volumeRatio":0.534465,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1737090000000,"strike":"22.5","timestamp":1713282934229,"price":1.0299999713897705,"volume":2000,"amount":206000,"type":"-"},{"symbol":"PFE","call":true,"expireDate":1768539600000,"strike":"40.0","timestamp":1713280091730,"price":0.7099999785423279,"volume":1235,"amount":87685,"type":"-"}]}},"requestUrl":"/m/hq/s/PFE","defaultTab":"news","newsList":[{"id":"2427649730","title":"辉瑞下跌1.21%，报26.02美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427649730","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427649730?lang=zh_cn&edition=full","pubTime":"2024-04-13 00:40","pubTimestamp":1712940003,"startTime":"0","endTime":"0","summary":"4月13日，辉瑞(PFE)盘中下跌1.21%，截至00:40，报26.02美元/股，成交3.29亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：5月1日，辉瑞将于(美东)盘前披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/13004040224308.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426785627","title":"BUZZ-摩根大通认为辉瑞公司的 COVID 治疗药物 Paxlovid 第一季度销售额有所增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2426785627","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426785627?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:48","pubTimestamp":1712922482,"startTime":"0","endTime":"0","summary":"** 根据目前Paxlovid的发展趋势，券商认为PFE的全年预测有上调空间，但预计PFE不会上调预测。** 预计第一季度美国Paxlovid总销售额为10亿美元，而LSEG预计为11.2亿美元 ** 补充说，COVID 的上扬不足以在短期内推动股价，并称 PFE 需要在管线方面取得进一步进展，才能改变当前的股价走势。** 预计 PFE 的 COVID 疫苗 Comirnaty 大约 80-90% 的销售额将在今年下半年实现，因此券商认为第一季度的业绩没有什么额外的亮点，估计 Comirnaty 的销售额约为 5.5 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426783006","title":"BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2426783006","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426783006?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:37","pubTimestamp":1712921821,"startTime":"0","endTime":"0","summary":"    4月12日 - ** Nurix Therapeutics Inc 的    股价在隔夜后续定价后盘前下跌 5.3%，报 16.30 美元。** 生物制药公司周四晚些时候宣布，  ~1170万股，包括150万份预筹资认股权证，发行价为15美元，筹资总额为1.75亿美元。** Nurix本月早些时候宣布延长与吉利德科学公司  的合作。2023 年第四季度，该公司与辉瑞  达成新的合作。** Nurix 拥有约 4 920 万股已发行股票，市值约 8.46 亿美元** 截至本周四，公司股价已累计上涨 67** 摩根大通、Piper Sandler 和 Stifel 担任股票发行的账簿管理人","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426422642","title":"隔夜美股全复盘(4.11)| 三大股指集体收跌，美国CPI数据连续第三个月高于预期，股市承压于美国CPI数据后的降息预期收缩，英伟达逆势涨近2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426422642","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2426422642?lang=zh_cn&edition=full","pubTime":"2024-04-11 07:18","pubTimestamp":1712791107,"startTime":"0","endTime":"0","summary":"三大股指集体收跌，美国CPI数据连续第三个月高于预期，股市承压于美国CPI数据后的降息预期收缩，英伟达逆势涨近2%","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/717886","is_publish_highlight":false,"gpt_icon":1},{"id":"2426108847","title":"辉瑞(PFE.US)RSV疫苗用于18-59岁高危人群三期临床成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2426108847","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426108847?lang=zh_cn&edition=full","pubTime":"2024-04-10 09:13","pubTimestamp":1712711625,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月9日，辉瑞宣布RSV疫苗Abrysvo用于18-59岁高危人群的三期临床获得积极数据，研究达到主要重点，免疫响应非劣效于60岁以上人群。辉瑞计划递交这一人群的上市申请。据了解，RSV高危人群是指特定慢性疾病的成年人。对于18-49岁成年人，9.5%的人群患有慢性疾病使得RSV感染风险提高，50-64岁这一比例则提高到24.3%。这些慢性疾病包括哮喘、糖尿病、COPD等。B组入组200例免疫不全18岁以上人群，其中一般为60岁以上人群。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100368.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426577116","title":"BUZZ-辉瑞公司在针对 60 岁以下高风险成人的研究中成功注射 RSV 疫苗，从而使其业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2426577116","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426577116?lang=zh_cn&edition=full","pubTime":"2024-04-09 22:59","pubTimestamp":1712674751,"startTime":"0","endTime":"0","summary":"** PFE表示，它计划提交研究结果，以寻求扩大该疫苗在18至59岁成年人中的批准范围。** 试验涉及 681 名 18 至 59 岁的成年人，他们患有哮喘、糖尿病和慢性阻塞性肺病等疾病，这些疾病会增加 RSV 的风险** RSV 通常会引起类似感冒的症状，是导致幼儿和老年人肺炎的主要原因。** PFE 去年推出了针对老年人和孕妇的 Abrysvo，以保护婴儿免受病毒感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426133051","title":"辉瑞上涨3.14%，报27.42美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426133051","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426133051?lang=zh_cn&edition=full","pubTime":"2024-04-09 22:26","pubTimestamp":1712672805,"startTime":"0","endTime":"0","summary":"4月9日，辉瑞(PFE)盘中上涨3.14%，截至22:26，报27.42美元/股，成交3.12亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：5月1日，辉瑞将于(美东)盘前披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/09222640170758.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425343189","title":"辉瑞研究表明P药并非“新冠神药”， 还有必要吃吗","url":"https://stock-news.laohu8.com/highlight/detail?id=2425343189","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2425343189?lang=zh_cn&edition=full","pubTime":"2024-04-08 14:31","pubTimestamp":1712557860,"startTime":"0","endTime":"0","summary":"上周末，一项由辉瑞抗病毒药物开发负责人领衔的研究结果显示，新冠期间被称为“新冠神药”的Paxlovid在缩短新冠持续症状时间方面并没有显著效果。其中，共有654名参与者服用Paxlovid，634名参与者服用安慰剂。缓解新冠症状持续时间为该临床试验的主要终点。P药组有5名参与者因新冠住院或死亡，安慰剂组有10名参与者因新冠住院或死亡。过去一年来，辉瑞股价累计跌幅超过35%。不过，新冠药物的研发仍在进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081432427a514b10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081432427a514b10&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424796018","title":"辉瑞下跌1.22%，报27.22美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424796018","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424796018?lang=zh_cn&edition=full","pubTime":"2024-04-04 03:20","pubTimestamp":1712172023,"startTime":"0","endTime":"0","summary":"4月4日，辉瑞(PFE)盘中下跌1.22%，截至03:20，报27.22美元/股，成交6.63亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：4月1日，辉瑞获Cantor Fitzgerald重申评级Overweight，目标价上调至45美元。5月7日，辉瑞将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/04032040122430.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424979260","title":"Roivant公司的抗炎药物在中期研究中获得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2424979260","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2424979260?lang=zh_cn&edition=full","pubTime":"2024-04-02 19:00","pubTimestamp":1712055650,"startTime":"0","endTime":"0","summary":" Bhanvi Satija    路透社4月2日 - Roivant Sciences   周二称，在一项中期研究中，其治疗非感染性葡萄膜炎的实验性药物有助于减轻炎症性眼病的症状。目前唯一获批的针对非感染性葡萄膜炎病因的疗法是艾伯维的   Humira，该药已于2023年停止专利。Roivant公司周二还表示，公司董事会已经批准了一项回购价值高达15亿美元公司股票的计划，其中包括从住友制药  回购6.48亿美元的股票。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424358760","title":"冯德莱恩陷“辉瑞门”，欧洲检察官办公室介入调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2424358760","media":"观察者网","top":-1,"share":"https://www.laohu8.com/m/news/2424358760?lang=zh_cn&edition=full","pubTime":"2024-04-02 10:30","pubTimestamp":1712025022,"startTime":"0","endTime":"0","summary":"报道称，冯德莱恩与布拉的短信交流被称为“辉瑞门”事件。列日检察官办公室发言人日前透露，欧洲检察官办公室已在几个月前接手对冯德莱恩的调查，但目前还没有人受到指控。欧洲检察官办公室的介入，可能导致冯德莱恩在辉瑞疫苗交易中扮演的角色受到进一步审查，或将对冯德莱恩寻求连任造成影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8YRvRCqJOs4","is_publish_highlight":false,"gpt_icon":0},{"id":"2424745349","title":"托菲茨杰拉德公司：重申Pfizer(PFE.US)评级，由增持调整至增持评级，目标价45.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424745349","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2424745349?lang=zh_cn&edition=full","pubTime":"2024-04-01 21:53","pubTimestamp":1711979608,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Pfizer(PFE.US)评级，由增持调整至增持评级，目标价45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040122071787d0ef0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040122071787d0ef0d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2423125514","title":"更新 2-美国疾病预防控制中心提醒医疗服务提供者注意脑膜炎球菌疾病的增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2423125514","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2423125514?lang=zh_cn&edition=full","pubTime":"2024-03-29 04:19","pubTimestamp":1711657176,"startTime":"0","endTime":"0","summary":"今年 10 月，美国食品和药物管理局批准了  辉瑞公司的  疫苗 Penbraya，这是第一种可预防五个脑膜炎球菌群的疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2423146739","title":"辉瑞上涨1.22%，报28.12美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2423146739","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2423146739?lang=zh_cn&edition=full","pubTime":"2024-03-29 01:43","pubTimestamp":1711647830,"startTime":"0","endTime":"0","summary":"3月29日，辉瑞(PFE)盘中上涨1.22%，截至01:43，报28.12美元/股，成交4.65亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：5月7日，辉瑞将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/29014340044493.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422913574","title":"CDE受理安斯泰来和辉瑞的EV+帕博利珠单抗一线治疗晚期膀胱癌sBLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2422913574","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422913574?lang=zh_cn&edition=full","pubTime":"2024-03-28 14:24","pubTimestamp":1711607040,"startTime":"0","endTime":"0","summary":"此次用于一线治疗的联合用药疗法sBLA是基于一项3期临床试验EV-302的结果。安全性结果与之前报告的联合疗法结果一致，未发现新的安全性问题。密切监测患者的皮肤反应。对疑似SJS或TEN或严重的皮肤反应，应立即停用enfortumab vedotin并考虑转诊至专业护理。安斯泰来警戒声明 本新闻稿中，有关当前计划、估计、战略和信念以及其他非历史事实的陈述，均为关于安斯泰来未来表现的前瞻性陈述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4373421_ZH73421_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422094331","title":"辉瑞上涨1.21%，报27.93美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2422094331","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422094331?lang=zh_cn&edition=full","pubTime":"2024-03-28 00:42","pubTimestamp":1711557742,"startTime":"0","endTime":"0","summary":"3月28日，辉瑞(PFE)盘中上涨1.21%，截至00:42，报27.93美元/股，成交3.53亿美元。财务数据显示，截至2023年12月31日，辉瑞收入总额584.96亿美元，同比减少41.7%；归母净利润21.19亿美元，同比减少93.25%。大事提醒：5月7日，辉瑞将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/28004240025063.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422793793","title":"辉瑞公司董事长艾伯乐：辉瑞会一直在中国投资发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2422793793","media":"中国新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2422793793?lang=zh_cn&edition=full","pubTime":"2024-03-27 15:04","pubTimestamp":1711523099,"startTime":"0","endTime":"0","summary":"3月24日下午举行了“大健康产业专题研讨会”，辉瑞公司董事长、首席执行官艾伯乐在“对话”环节的发言中表示：辉瑞非常重视科学创新，希望和中国的科研机构，以及中国的生物制药生态系统结成紧密的纽带。对于辉瑞公司下一阶段在中国市场的投资运营计划，艾伯乐表示，辉瑞会一直在中国投资发展，因为中国是一个非常有前景的市场。艾伯乐提出，治疗癌症和艾滋病的药物，以及与人类精神卫生相关的药物是制药产业重点关注的领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032715061187bb2bba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032715061187bb2bba&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422530326","title":"辉瑞(PFE.US)及阿斯利康(AZN.US)拟在华推出多个新药或适应症申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422530326","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422530326?lang=zh_cn&edition=full","pubTime":"2024-03-26 14:41","pubTimestamp":1711435260,"startTime":"0","endTime":"0","summary":"辉瑞董事长兼首席执行官艾伯乐在北京出席“投资中国”活动致词时提到，对中国的创新药物开发前景感兴趣，计划明年前在中国提交17个新药或适应症申请。阿斯利康首席执行官苏博科亦称，目前研发管线逾200个项目，预计未来5年将在中国推出约100个新药及适应症申请。另外，艾伯乐较早时表示，中国市场潜力巨大，存在着许多机会，相信在数年内中国就会成为生物科技创新的尖端。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211125141320348_s.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1337065/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422104425","title":"尹力分别会见诺华集团、辉瑞公司、丹纳赫集团负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=2422104425","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2422104425?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:32","pubTimestamp":1711373520,"startTime":"0","endTime":"0","summary":"据北京日报消息，3月25日下午，市委书记尹力分别会见了瑞士诺华集团全球首席执行官万思瀚、美国辉瑞公司董事长兼首席执行官艾伯乐和美国丹纳赫集团全球总裁兼首席执行官毕睿宁。尹力介绍了北京市经济社会发展及居民健康状况。艾伯乐表示，中国医药健康产业市场规模巨大，北京创新能力强、营商环境一流，为医药企业提供了广阔机遇，辉瑞公司愿同北京在创新研发、应对公共卫生挑战等领域进一步深化拓展合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252135467a4ee819&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252135467a4ee819&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422238519","title":"辉瑞宣布将40%的研发费用投入癌症创新疗法研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2422238519","media":"钛媒体","top":-1,"share":"https://www.laohu8.com/m/news/2422238519?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:05","pubTimestamp":1711368335,"startTime":"0","endTime":"0","summary":"钛媒体App 3月25日消息，辉瑞董事长兼首席执行官艾伯乐博士（Albert Bourla）在中国发展高层论坛2024上强调了辉瑞对于创新与合作的重视，并表示辉瑞用于推进癌症创新疗法相关的研发投入已占比整体研发投入的大约40%。目前辉瑞已进入中国35年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032520054087b2fcdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032520054087b2fcdf&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":-0.0727},{"period":"3month","weight":-0.0851},{"period":"6month","weight":-0.1751},{"period":"1year","weight":-0.371},{"period":"ytd","weight":-0.1}],"compareEarnings":[{"period":"1week","weight":-0.0275},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0622},{"period":"6month","weight":0.1726},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.0613}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.00126},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.007167},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015985},{"month":4,"riseRate":0.6,"avgChangeRate":0.019707},{"month":5,"riseRate":0.5,"avgChangeRate":0.00626},{"month":6,"riseRate":0.5,"avgChangeRate":0.002739},{"month":7,"riseRate":0.477273,"avgChangeRate":0.010684},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000087},{"month":9,"riseRate":0.454545,"avgChangeRate":0.004027},{"month":10,"riseRate":0.659091,"avgChangeRate":0.014878},{"month":11,"riseRate":0.704545,"avgChangeRate":0.030213},{"month":12,"riseRate":0.5,"avgChangeRate":0.0093}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}